Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.
Here’s a brief overview of medications for neurological disorders that were approved or granted a new indication or an additional formulation by the FDA in the past 6 months.
Scroll through the slides for details about new treatments for multiple sclerosis, narcolepsy, migraine, Parkinson disease, pain, and Lennox-Gastaut syndrome.
Multiple Sclerosis:Mavenclad (cladribine) is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease, in adults. (Approved 03/29/2019, EMD Serono, Inc.)
Multiple Sclerosis:Mayzent (siponimod) is a sphingosine-1-phosphate receptor modulator for the treatment of adults with relapsing forms of MS, including secondary progressive MS with active disease, relapsing remitting MS, and clinically isolated syndrome. (Approved 03/26/2019, Novartis Pharmaceuticals Corporation.)
Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome:Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor for the treatment of excessive sleepiness in adults with narcolepsy or obstructive sleep apnea. (Approved 03/20/2019, Jazz Pharmaceuticals.)
Migraine: Tosymra (sumatriptan) nasal spray is indicated for the acute treatment of migraine with or without aura in adults. (Approved 01/25/2019, Dr. Reddy’s Laboratories, Inc.)
Parkinson Disease:Inbrija (levodopa) is an oral inhalation formulation of levodopa for the intermittent treatment of “off” episodes in patients with Parkinson disease who are taking a carbidopa/levodopa regimen. (Approved 12/21/2018, Acorda Therapeutics, Inc.)
Pain:Dsuvia (sufentanil) sublingual tablets are indicated for the management of acute pain in adults that is severe enough to require an opioid analgesic in certified medically supervised healthcare settings. (Approved 11/02/2018, AcelRx Pharmaceuticals, Inc.)
Lennox-Gastaut Syndrome: Sympazan (clobazam) is an oral film benzodiazepine formulation for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age or older. (Approved 11/01/2018, Aquestive Therapeutics, Inc.)